https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-15 / Cancer Res. 2013 Apr;73(8):2493-504
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-15 / Cancer Res. 2013 Apr;73(8):2493-5042013-02-15 00:00:002019-02-15 08:39:50Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-11 / J. Clin. Oncol. 2013 Mar;31(8):1021-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-11 / J. Clin. Oncol. 2013 Mar;31(8):1021-82013-02-11 00:00:002019-02-15 08:35:16Harnessing the immune system for the treatment of non-small-cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-01 / BioDrugs 2013 Feb;27(1):35-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-01 / BioDrugs 2013 Feb;27(1):35-532013-02-01 00:00:002021-11-15 16:56:59Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-01 / J. Immunother. 2013 Feb;36(2):152-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-01 / J. Immunother. 2013 Feb;36(2):152-72013-02-01 00:00:002019-02-15 08:46:30Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-01 / Immunotherapy 2013 Feb;5(2):155-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-01 / Immunotherapy 2013 Feb;5(2):155-672013-02-01 00:00:002019-02-15 08:46:29Vaccine strategies for glioblastoma: progress and future directions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-01 / Hum Vaccin Immunother 2013 May;9(5):1069-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-01 / Hum Vaccin Immunother 2013 May;9(5):1069-722013-02-01 00:00:002024-08-26 09:28:16Current status of immunotherapy for the treatment of biliary tract cancer
